04/06/2010 - SPARK Ventures to realise its investment in Complinet  |  06/05/2010 - CNBC launches on Livestation  |  17/12/2009 - Livestation adds CNN International to its channel offering  |  IMImobile raises $13m of equity for expansion  |  18/09/2009 - Founders of SPARK Ventures’ portfolio company notonthehighstreet.com win ‘Entrepreneur of the Year'  |  28/08/2009 - SPARK Ventures realises its investment in Unanimis  |  19/06/2009 - Telecom Express and IMImobile join forces to launch IMEXmobile - Mobile Interaction Specialist

Biological therapies:

Celldex Therapeutics, Inc.

GlycArt AG

Glycoform

Haemostatix

Oxford BioMedica plc

Oxitec

Diagnostics & point-of-care:

IDG

Oxford Biosensors

Oxford Immunotec

Vivacta Limited

Disease Management & wellness:

Gemini Biomedical

Genosis plc

Instrumentation:

Teraview

IT in Healthcare:

Mirada Solutions

Medical Devices & Medical Technology:

(No investments to date)

Nanotechnology:

Oxonica plc

Pharmaceuticals and Speciality pharmaceuticals:

Allergy Therapeutics plc

Cyclacel Inc

Lectus Therapeutics

Medigene AG

Oxagen

PowerMed

Sterix

Vernalis plc

Xention

Telemedicine & e-Health:

(No investments to date)

 

GlycArt, was sold to Roche, one of the world’s leading pharmaceutical companies, for approximately CHF 235 million (£104 million) in July 2006, making it one of the biggest biotech deals of the year.

Quester invested in November 2003 and achieved a return of approximately 7x cost.

GlycArt is a Swiss biotechnology company focused on the development and commercialisation of a new generation of antibody products based on its proprietary GlycoMAb technology.  GlycoMAb has the potential to generate best-in-class antibody therapeutics in disease areas such as oncology, where Roche is the global market leader. In addition, Roche acquired GlycArt’s development pipeline, including three monoclonal antibodies in preclinical development for cancer.   

View website